Drugmaker Catalent reaches an agreement to buy closely held Paragon Bioservices, the latest deal in the burgeoning gene-therapy treatment space.
Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.
Shares of Zogenix plunge after the FDA rejects an initial marketing application for one of its more promising epilepsy treatment drugs.
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
Coverage of Teva Pharmaceutical is initiated at market perform at BMO with a price target of $18.
Mayzent tablets to treat relapsing multiple sclerosis have been approved by the FDA. But the treatment comes with a hefty price tag.
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
David Tepper's Appaloosa LP renews calls for changes at the top.
Johnson & Johnson received FDA approval for a nasal spray designed to treat patients with depression.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.